X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2222) 2222
Publication (175) 175
Book Review (87) 87
Book Chapter (21) 21
Book / eBook (20) 20
Newspaper Article (9) 9
Magazine Article (8) 8
Newsletter (7) 7
Web Resource (6) 6
Conference Proceeding (3) 3
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1890) 1890
platelet aggregation inhibitors - therapeutic use (1168) 1168
index medicus (1050) 1050
male (784) 784
female (731) 731
aged (592) 592
middle aged (590) 590
cardiac & cardiovascular systems (449) 449
platelet aggregation inhibitors - economics (448) 448
ticlopidine - analogs & derivatives (440) 440
risk factors (426) 426
aspirin (417) 417
treatment outcome (407) 407
clopidogrel (368) 368
aspirin - therapeutic use (354) 354
cost-benefit analysis (354) 354
ticlopidine - therapeutic use (323) 323
pharmacology & pharmacy (316) 316
platelet aggregation inhibitors - adverse effects (310) 310
platelet aggregation inhibitors - administration & dosage (308) 308
adult (241) 241
drug therapy, combination (237) 237
animals (234) 234
mortality (231) 231
anticoagulants - therapeutic use (227) 227
stroke (220) 220
acute coronary syndromes (218) 218
drug therapy (216) 216
medicine, general & internal (215) 215
prevention (215) 215
blood platelets (214) 214
analysis (209) 209
myocardial-infarction (208) 208
percutaneous coronary intervention (207) 207
time factors (205) 205
aged, 80 and over (189) 189
care and treatment (189) 189
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (188) 188
peripheral vascular disease (183) 183
heart attacks (181) 181
ticlopidine - economics (178) 178
coronary heart disease (176) 176
platelet aggregation inhibitors - pharmacology (175) 175
cardiovascular disease (174) 174
risk (174) 174
cardiology (169) 169
retrospective studies (166) 166
abridged index medicus (162) 162
thrombosis (158) 158
anticoagulants (156) 156
secondary prevention (154) 154
aggregation (153) 153
hematology (153) 153
stents (152) 152
therapy (152) 152
acute myocardial-infarction (151) 151
health aspects (149) 149
antiplatelet therapy (148) 148
medicine & public health (148) 148
research (148) 148
myocardial infarction - drug therapy (147) 147
cardiovascular diseases (145) 145
randomized controlled trials as topic (145) 145
cardiac patients (141) 141
stroke - prevention & control (141) 141
angioplasty (135) 135
acute coronary syndrome - drug therapy (133) 133
prospective studies (133) 133
angioplasty, balloon, coronary (132) 132
cardiovascular diseases - prevention & control (131) 131
risk assessment (129) 129
surgery (129) 129
platelets (128) 128
aspirin - administration & dosage (127) 127
platelet aggregation - drug effects (127) 127
aspirin - economics (124) 124
drug costs (124) 124
management (116) 116
hemorrhage - chemically induced (115) 115
outcomes (114) 114
ticlopidine - adverse effects (114) 114
cardiovascular (113) 113
fibrinolytic agents - therapeutic use (111) 111
trial (110) 110
platelet aggregation (108) 108
follow-up studies (107) 107
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (106) 106
antibodies, monoclonal - therapeutic use (105) 105
coronary disease - drug therapy (105) 105
immunoglobulin fab fragments - therapeutic use (105) 105
practice guidelines as topic (105) 105
usage (105) 105
abciximab (104) 104
clinical trials as topic (104) 104
cost-effectiveness (104) 104
disease (104) 104
myocardial infarction (104) 104
aspirin - adverse effects (103) 103
intervention (103) 103
acute coronary syndrome (102) 102
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2212) 2212
French (19) 19
Spanish (16) 16
German (10) 10
Italian (10) 10
Swedish (6) 6
Japanese (4) 4
Russian (3) 3
Dutch (2) 2
Portuguese (2) 2
Chinese (1) 1
Danish (1) 1
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Polish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10013, pp. 61 - 69
Summary Background WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible... 
Internal Medicine | Drug Costs | Platelet Aggregation Inhibitors - economics | Cardiovascular Diseases - drug therapy | Humans | Income | Malaysia | Secondary Prevention | Aspirin - supply & distribution | Urban Population | Angiotensin-Converting Enzyme Inhibitors - supply & distribution | Angiotensin-Converting Enzyme Inhibitors - economics | Sweden | Pakistan | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Iran | Rural Population | China | Adrenergic beta-Antagonists - economics | Brazil | Poland | Aspirin - therapeutic use | Aspirin - economics | Chile | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Agents - economics | Colombia | Argentina | Platelet Aggregation Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | United Arab Emirates | Adrenergic beta-Antagonists - supply & distribution | India | Pharmacies | Canada | Cardiovascular Agents - supply & distribution | Cardiovascular Agents - therapeutic use | Bangladesh | Family Characteristics | Developed Countries | Turkey | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | South Africa | Zimbabwe | Developing Countries | Drugs | Prevention | Usage | Cardiovascular diseases | Analysis | Disease prevention | Cardiovascular disease | Costs | Health care access | Preventive medicine | Health risk assessment | Klinisk medicin | Clinical Medicine
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 02/2008, Volume 99, Issue 2, pp. 295 - 304
The risk of stroke in atrial fibrillation (AF) needs to be assessed in each patient to determine the clinical and cost-effectiveness of thromboprophylaxis,... 
cost-effectiveness | Stroke | thromboembolism | Atrial fibrillation | risk modeling | echocardiography | thromboprophylaxis | anticoagulation | stroke prevention | Theme Issue Article | Risk modeling | Stroke prevention | Echocardiography | Anticoagulation | Thromboprophylaxis | Thromboembolism | Cost-effectiveness | PREDICTING STROKE | PREVENTION | FOLLOW-UP | MITRAL REGURGITATION | stroke | ASPIRIN | atrial fibrillation | WARFARIN | ANTITHROMBOTIC THERAPY | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ISCHEMIC-STROKE | ELDERLY-PATIENTS | Drug Costs | Smoking - adverse effects | Platelet Aggregation Inhibitors - economics | Age Factors | Humans | Anticoagulants - economics | Male | Patient Selection | Fibrinolytic Agents - adverse effects | Atrial Fibrillation - economics | Thromboembolism - prevention & control | Fibrinolytic Agents - therapeutic use | Heart Diseases - complications | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Risk Assessment | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | Stroke - economics | Anticoagulants - therapeutic use | Diabetes Complications - drug therapy | Treatment Outcome | Thromboembolism - etiology | Anticoagulants - adverse effects | Diabetes Complications - etiology | Thromboembolism - economics | Health Care Costs | Stroke - etiology | Algorithms | Fibrinolytic Agents - economics | Cost-Benefit Analysis | Sex Factors | Thromboembolism - complications | Hypertension - complications | Aged | Hemorrhage - chemically induced | Research Design | Index Medicus
Journal Article
JAMA Internal Medicine, ISSN 2168-6106, 08/2017, Volume 177, Issue 8, pp. 1093 - 1101
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 02/2014, Volume 160, Issue 4, pp. 221 - 232
Background: The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to... 
MEDICINE, GENERAL & INTERNAL | ARTERY-BYPASS SURGERY | CYP2C19 GENOTYPE | TIMI 38 TRIAL | CARDIOVASCULAR EVENTS | QUALITY-OF-LIFE | PLATO PLATELET INHIBITION | SIROLIMUS-ELUTING STENTS | ELEVATION MYOCARDIAL-INFARCTION | DECISION-ANALYTIC MODEL | PATIENT OUTCOMES TRIAL | Platelet Aggregation Inhibitors - economics | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Thiophenes - adverse effects | Ticlopidine - therapeutic use | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Drugs, Generic - economics | Piperazines - economics | Drugs, Generic - therapeutic use | Adenosine - adverse effects | Adenosine - therapeutic use | Coronary Thrombosis - prevention & control | Ticlopidine - adverse effects | Ticlopidine - economics | Thiophenes - economics | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Quality-Adjusted Life Years | Direct Service Costs | Risk Factors | Decision Support Techniques | Genotype | Piperazines - therapeutic use | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Polymorphism, Genetic | Acute Coronary Syndrome - drug therapy | Drugs, Generic - adverse effects | Cytochrome P-450 CYP2C19 | Adenosine - analogs & derivatives | Cost-Benefit Analysis | Alleles | Acute Coronary Syndrome - surgery | Adenosine - economics | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Aggregation | Care and treatment | Blood platelets | Genetic aspects | Research | Coronary heart disease | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
European Heart Journal, ISSN 0195-668X, 01/2013, Volume 34, Issue 3, pp. 220 - 228
Journal Article
Circulation, ISSN 0009-7322, 01/2010, Volume 121, Issue 1, pp. 71 - 79
Background-In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by... 
Infarction | Coronary disease | Thrombus | Cost- benefit analysis | Revascularization | revascularization | CARDIAC & CARDIOVASCULAR SYSTEMS | CONFIDENCE-INTERVALS | CARDIOVASCULAR EVENTS | infarction | thrombus | coronary disease | IMPACT | cost-benefit analysis | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | CLINICAL-OUTCOMES | Platelet Aggregation Inhibitors - economics | Prasugrel Hydrochloride | Thiophenes - therapeutic use | United States - epidemiology | Myocardial Infarction - mortality | Follow-Up Studies | Ticlopidine - therapeutic use | Acute Coronary Syndrome - economics | Humans | Acute Coronary Syndrome - mortality | Hemorrhage - mortality | Piperazines - economics | Angioplasty, Balloon, Coronary | Drug Costs - statistics & numerical data | Life Expectancy | Ticlopidine - economics | Myocardial Infarction - economics | Thiophenes - economics | Stroke - mortality | Platelet Aggregation Inhibitors - therapeutic use | Databases, Factual | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Thrombolytic Therapy - economics | Combined Modality Therapy | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Outcome and Process Assessment (Health Care) - economics | Myocardial Infarction - drug therapy | Cost-Benefit Analysis | Hospitalization - economics | Usage | Patient outcomes | Clopidogrel | Drug therapy | Comparative analysis | Health aspects | Heart attack
Journal Article
Catheterization and Cardiovascular Interventions, ISSN 1522-1946, 10/2016, Volume 88, Issue 4, pp. 605 - 616
Journal Article
Circulation, ISSN 0009-7322, 03/2008, Volume 117, Issue 10, pp. 1261 - 1268
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2013, Volume 11, Issue 1, pp. 81 - 91
Background:  The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary... 
clopidogrel | cost‐effectiveness | prasugrel | antiplatelet therapy | genetic testing | acute coronary syndromes | Antiplatelet therapy | Prasugrel | Clopidogrel | Genetic testing | Acute coronary syndromes | Cost-effectiveness | cost-effectiveness | LAST YEAR | CYP2C19 GENOTYPE | TREATED PATIENTS | BYPASS GRAFT-SURGERY | ATRIAL-FIBRILLATION | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | OF-CARE | CLINICAL-OUTCOMES | Prasugrel Hydrochloride | Predictive Value of Tests | Thiophenes - therapeutic use | Percutaneous Coronary Intervention - mortality | Acute Coronary Syndrome - economics | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Thiophenes - metabolism | Medicare - economics | Models, Economic | Pharmacogenetics - economics | Time Factors | Ticlopidine - economics | Myocardial Infarction - etiology | Insurance, Health, Reimbursement - economics | Quality-Adjusted Life Years | Genetic Predisposition to Disease | Risk Assessment | Gene Frequency | Risk Factors | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Phenotype | Acute Coronary Syndrome - therapy | Thrombosis - genetics | Percutaneous Coronary Intervention - economics | Percutaneous Coronary Intervention - adverse effects | Thrombosis - economics | Drug Costs | Platelet Aggregation Inhibitors - economics | Markov Chains | Ticlopidine - therapeutic use | United States | Acute Coronary Syndrome - mortality | Piperazines - economics | Piperazines - metabolism | Computer Simulation | Hemorrhage - etiology | Ticlopidine - metabolism | Thiophenes - economics | Platelet Aggregation Inhibitors - metabolism | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Decision Support Techniques | Kaplan-Meier Estimate | Treatment Outcome | Cerebrovascular Disorders - etiology | Aryl Hydrocarbon Hydroxylases - metabolism | Disease-Free Survival | Health Care Costs | Cytochrome P-450 CYP2C19 | Cost-Benefit Analysis | Acute Coronary Syndrome - diagnosis | Acute Coronary Syndrome - genetics | Genetic Testing - economics | Transluminal angioplasty | Care and treatment | Medicare | Analysis | Cardiac patients | Cytochrome P-450 | Markov processes | Cost benefit analysis | Coronary heart disease | Genetic screening | Angina pectoris | Genotype & phenotype
Journal Article